JP7453230B2 - 骨髄増殖性障害を治療する方法 - Google Patents

骨髄増殖性障害を治療する方法 Download PDF

Info

Publication number
JP7453230B2
JP7453230B2 JP2021530108A JP2021530108A JP7453230B2 JP 7453230 B2 JP7453230 B2 JP 7453230B2 JP 2021530108 A JP2021530108 A JP 2021530108A JP 2021530108 A JP2021530108 A JP 2021530108A JP 7453230 B2 JP7453230 B2 JP 7453230B2
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
composition according
ruxolitinib
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519425A (ja
Inventor
センデロビッチ，エイドリアン
クーパー，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Constellation Pharmaceuticals Inc
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of JP2022519425A publication Critical patent/JP2022519425A/ja
Priority to JP2024034717A priority Critical patent/JP2024063214A/ja
Application granted granted Critical
Publication of JP7453230B2 publication Critical patent/JP7453230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021530108A 2018-11-27 2018-11-27 骨髄増殖性障害を治療する方法 Active JP7453230B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024034717A JP2024063214A (ja) 2018-11-27 2024-03-07 骨髄増殖性障害を治療する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034717A Division JP2024063214A (ja) 2018-11-27 2024-03-07 骨髄増殖性障害を治療する方法

Publications (2)

Publication Number Publication Date
JP2022519425A JP2022519425A (ja) 2022-03-24
JP7453230B2 true JP7453230B2 (ja) 2024-03-19

Family

ID=64734125

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530108A Active JP7453230B2 (ja) 2018-11-27 2018-11-27 骨髄増殖性障害を治療する方法
JP2024034717A Pending JP2024063214A (ja) 2018-11-27 2024-03-07 骨髄増殖性障害を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024034717A Pending JP2024063214A (ja) 2018-11-27 2024-03-07 骨髄増殖性障害を治療する方法

Country Status (8)

Country Link
JP (2) JP7453230B2 (enrdf_load_stackoverflow)
KR (2) KR20250004357A (enrdf_load_stackoverflow)
AU (1) AU2018451360B2 (enrdf_load_stackoverflow)
BR (1) BR112021010134A2 (enrdf_load_stackoverflow)
CA (1) CA3120973A1 (enrdf_load_stackoverflow)
EA (1) EA202191489A1 (enrdf_load_stackoverflow)
SG (1) SG11202105279SA (enrdf_load_stackoverflow)
WO (1) WO2020112086A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112939A1 (en) 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
AU2020356575A1 (en) 2019-09-27 2022-04-14 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
MX2022014254A (es) 2020-05-13 2023-02-16 Disc Medicine Inc Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis.
KR20230048042A (ko) * 2020-08-04 2023-04-10 콘스텔레이션 파마슈티칼스, 인크. 혈소판 증가증의 치료를 위한 2-((4s)-6-(4-클로로페닐)-1-메틸-4h-벤조[c]이속사졸로[4,5-e]아제핀-4-일)아세트아미드

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544847A (ja) 2010-12-02 2013-12-19 コンステレーション・ファーマシューティカルズ・インコーポレイテッド ブロモドメイン阻害剤およびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3157928T3 (pl) 2014-06-20 2019-07-31 Constellation Pharmaceuticals, Inc. Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544847A (ja) 2010-12-02 2013-12-19 コンステレーション・ファーマシューティカルズ・インコーポレイテッド ブロモドメイン阻害剤およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Cell，2018年01月，Vol.33,pp.29-43
J.Med.Chem.，2016年，Vol.59, pp.1330-1339

Also Published As

Publication number Publication date
SG11202105279SA (en) 2021-06-29
JP2022519425A (ja) 2022-03-24
BR112021010134A2 (pt) 2021-08-24
AU2018451360B2 (en) 2022-05-26
KR20210095904A (ko) 2021-08-03
AU2018451360A1 (en) 2021-06-10
EA202191489A1 (ru) 2021-09-10
JP2024063214A (ja) 2024-05-10
WO2020112086A1 (en) 2020-06-04
CA3120973A1 (en) 2020-06-04
KR102738936B1 (ko) 2024-12-06
KR20250004357A (ko) 2025-01-07

Similar Documents

Publication Publication Date Title
JP2024063214A (ja) 骨髄増殖性障害を治療する方法
US12070464B2 (en) Methods of treating myeloproliferative disorders
US20220168333A1 (en) Combination Treatment for Hematological Cancers
KR20180124055A (ko) 급성 골수성 백혈병의 치료를 위한 병용 요법
CN114828842A (zh) 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
WO2021091535A1 (en) Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
US20210187072A1 (en) Methods and compositions for reducing risk of relapse and prolonging survival in acute myeloid leukemia
JP2023550598A (ja) 骨髄線維症を治療する際に使用するためのｃｘｃｒ１／ｃｘｃｒ２阻害物質
EA047870B1 (ru) Способы лечения миелопролиферативных расстройств
EP4337213A1 (en) Use of pelabresib for treating anemias
WO2021091532A1 (en) Methods of treating myeloproliferative disorders
WO2020256739A1 (en) Methods of treating myeloproliferative disorders
TW202227077A (zh) Ｅｒｋ抑制劑用於治療骨髓纖維化之用途
WO2025002346A1 (zh) 含pd-l1小分子抑制剂的药物组合及其应用
WO2020257644A1 (en) Methods of treating myeloproliferative disorders
KR20240164549A (ko) 암 치료를 위한 metap2 억제제를 포함하는 조합
JP2020176145A (ja) 血液癌の併用療法
Garcia-Manero Spliceosome Mutations, IRAK4 and CA-4948 in MDS and AML

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20210708

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20210527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240307

R150 Certificate of patent or registration of utility model

Ref document number: 7453230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150